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Introduction
Apoptosis is a genetically programmed cell death con-
trolled by two diverse pathways, the receptor-mediat-
ed (extrinsic) pathway and the mitochondrial-mediated
(intrinsic) pathway [1]. There are numerous ligands of
TNF (tumor necrosis factor) superfamily that are
involved in apoptosis. Some members of this family
are TNFα, FasL/Apo1L/CD95L and TRAIL/Apo2L/
TNFSF10. They regulate many biological functions
including cell metabolism, proliferation, cytokine pro-
duction and apoptosis. Failure to undergo apoptosis
has been implicated in tumor development and resist-
ance to cancer therapy [1-3].
Tumor necrosis factor-related apoptosis-inducing
ligand (TRAIL) was originally identified in 1995 and
cloned on the basis of sequence homology to the FasL
and TNF [4]. TRAIL is characterized as a powerful
activator of programmed cell death in tumor cells with
no toxicity against normal tissues [5]. This feature has
greatly spurred research to explore the potential of
TRAIL as an anticancer therapy and the mechanisms
underlying its antitumor properties [6,7]. Endogenous
TRAIL exerts biological activity as an integral mem-
brane (type II transmembrane) protein expressed on
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Abstract: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL/Apo2L) is a member of TNF superfamily able
to induce programmed death in cancer cells with no toxicity against normal tissues. TRAIL mediate apoptosis follows bind-
ing to the two death receptors, TRAIL-R1 (DR4) and/or TRAIL-R2 (DR5). In this study we investigated the cytotoxic and
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ed for TRAIL sensitivity. The bladder cancer cells were incubated with human soluble recombinant TRAIL. Cytotoxicity
was measured by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-dimethyltetrazolium bromide) and LDH (lactate dyhydrogenase)
assays. Apoptosis was detected by flow cytometry with annexin V-FITC/propidium iodide and by fluorescence microscopy
with Hoechst 33342/annexin V-FITC/Ethidium Homodimer. The cell surface expression of TRAIL death receptors on blad-
der cancer were determined using flow cytometry with phycoerythrin-conjugated monoclonal anti-human TRAIL-R1 and
TRAIL-R2. Our investigations confirmed that SW780 cells were sensitive to TRAIL, and two other bladder cancer cell
lines, 647V and T24, were resistant to TRAIL induced apoptosis. We therefore examined the expression of TRAIL death
receptors on bladder cancer cell surfaces. We showed decreased expression of TRAIL-R2 receptor in TRAIL-resistant blad-
der cancer cells and increased expression of this death receptor in TRAIL-sensitive SW780 cells. The expression of TRAIL-
R1 receptor was similar in all bladder cancer cell lines. TRAIL is one of the promising candidates for cancer therapeutics.
However, some cancer cells are resistant to TRAIL-mediated apoptosis. It is therefore important to overcome this resistance
for the clinical use of TRAIL in cancer therapy. TRAIL death receptors are attractive therapeutic targets in cancer treatment.
The cytotoxic agents capable of up-regulating the expression of TRAIL-R1 and TRAIL-R2 can sensitize cancer cells to
TRAIL induced apoptosis.
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the surface of immune cells or soluble form, which is
released by immune cells. Both full-length membrane
expressed TRAIL and the soluble ligand can rapidly
induce apoptosis in a wide variety of human cancer
cells and xenographic tumor models [6-9].
TRAIL binds to five receptors: four type I trans-
membrane proteins TRAIL-R1,-R2,-R3,-R4 and one
soluble receptor (OPG). Among the various receptor-
ligand interactions possible within the TNF superfam-
ily, the TRAIL ligand-receptors system is the most
complex [10]. Two of these transmembrane receptors,
namely death receptor TRAIL-R1 (DR4) and death
receptor TRAIL-R2 (DR5, KILLER), contain death
domain (DD) through which TRAIL transmits an
apoptotic signal. TRAIL triggers apoptosis via interac-
tion with TRAIL death receptors present in target cells.
This intracellular DD of TRAIL-R1 and TRAIL-R2
have been found to be essential for induction of apop-
tosis following receptor ligation [11,12]. Two other
transmembrane receptors, called decoy receptors
TRAIL-R3 (DcR1) and TRAIL-R4 (DcR2) and one
soluble receptor, osteprotegerin (OPG) lacking a func-
tional DD, act as antagonistic receptor competing with
death receptors TRAIL-R1 and TRAIL-R2 for binding
to the TRAIL. Decoys receptors and OPG are involved
in negative regulation of apoptosis by sequestering
TRAIL and stimulating prosurvival signals [13].
TRAIL binds as a homotrimer to TRAIL-R1 and
TRAIL-R2, which results in trimerisation of the death
receptors and subsequent assembly of a death-induc-
ing signaling complex (DISC). At the DISC, the adap-
tor protein FAAD (Fas-associated-death domain) acts
as a bridge between the death receptor complex and
the initiator caspase 8. Upon recruitment by FADD,
caspase 8 will be activated and then activates down-
stream effector caspases such as caspases 3, 6 and 7,
which execute apoptosis. This death receptor initiated
apoptosis pathway is referred to as the extrinsic apop-
tosis pathway. Crosstalk exists between the extrinsic
pathway and the intrinsic one called mitochondrial-ini-
tiated apoptosis pathway through Bid. Caspase-8 also
mediates also cleavage of Bid (BH3-interacting
domain death agonist). Trucated Bid called tBid
translocates to the mitochondria where it interacts with
Bax (Bcl-2-associated X protein) and Bak (Bcl-2-ago-
nist/killer), stimulating the release of cytochrome c. In
the cytosol, cytochrome c binds the adaptor protein
Apaf-1 (apoptotic protease-activating factor-1) and
procaspase-9, forming the apoptosome and activating
caspase-9 which in turn activates executioner caspases
(caspase-3, -6, -7) leading to apoptosis [1,6,14]. 
Bladder cancer is the fourth most common malig-
nancy in men and eighth most common malignancy in
women. Transitional cell carcinoma (TCC) is observed
in above 90% of pathologic subtypes of bladder
tumors. A novel therapeutic strategies are required to
prevent bladder cancer recurrence and reduce risk of
tumor progression [15].
Targeting death receptors to trigger apoptosis in
tumor cells is an attractive concept for cancer therapy
including bladder tumors [16]. TRAIL appears to be a
relatively safe and promising candidate for clinical
application. Currently, phase I and phase II studies are
being initiated with human recombinant TRAIL or
agonistic monoclonal antibodies against TRAIL-R1
and/or TRAIL-R2 [14,17,18].
However, some cancer cells are resistant to TRAIL
induced apoptosis. The mutation or decreased expres-
sion of death receptors (TRAIL-R1 and/or TRAIL-R2)
and increased expression of antiapoptotic protein in
cancer cells are involved in TRAIL-resistance [19,20].
The combined treatment with TRAIL and anticancer
agents, such as chemotherapeutic drugs or ionizing
radiation, can overcome TRAIL-resistance and sensi-
tize cancer cells to TRAIL-mediated programmed cell
death [21]. 
Materials and methods
Reagents. Recombinant human TRAIL was purchased from
PeproTech Inc. (Rocky Hill, NJ, USA).
Cell culture. The experiments were performed on three human
bladder transitional cancer cell (TCC) lines derived from bladder
tumor obtained from DSMZ (German Collection of Microorgan-
isms and Cell Cultures, Braunschweig, Germany) and ATCC
(American Type Culture Collection, Manassas, VA, USA):
• SW780 line cells, cat. no. CRL-2169 – well differentiated tran-
sitional cells (G1),
• 647 line cells, cat. no. ACC-414 – moderately differentiated
transitional cells (G2),
• T24 line cells, cat. no. ACC-376 – poorly differentiated transi-
tional cells (G3).
The bladder cancer cells were grown in monolayer cultures in
75 cm2 plastic flasks (Nunc A/S Roskilde, Denmark): SW780 cells
in Leibovitz's, 647V and T24 cells in DMEM. All mediums were
supplemented with 10% of heat-inactivated fetal bovine serum
(FBS), 2 mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml
streptomycin. The cells were incubated at 37°C, SW780 cells in
100% air atmosphere, 647V and T24 cells in 95% air atmosphere
and 5% CO2. TCC cells were passaged three times a week. During
the experiments, cells were detached with 0.05% trypsin/ 0.02%
EDTA. Reagents for bladder cancer cell culture were purchased
from PAA The Cell Culture Company (Pasching, Austria). The
density of bladder cancer cells in each test was 1 × 106/ml for
SW780 cells and 0.5 × 106/ml for 647V and T24 cells.
MTT assay. The cytotoxic effect of TRAIL on bladder cancer cells
was measured by MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium) assay, as described [22,23]. TCC cells were
seeded onto a 96-well plate (Nunc A/S Roskilde, Denmark) 24
hours before the experiments. Various concentrations of rhsTRAIL
were added to the cells, and 20 hours later the medium was
removed and 20 μl MTT solutions (5 mg/ml) (Sigma Chemical
Company, MO, USA) were added to each well for 4 hours. The
resulting crystals were dissolved in DMSO (Sigma Chemical Com-
pany, MO, USA). Controls included native cells and medium
alone. The spectrophotometric absorbance of each well was meas-
ured using a microplate reader (ELx 800, Bio-Tek Instruments Inc.,
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Winooski, VT, USA) with a test wavelength of 550 nm. The data
on the cell proliferation and cytotoxic assays was obtained from
three separate experiments and for each test quadruplicate wells
were used. The percent cytotoxicity was calculated by the follow-
ing formula: percent cytotoxicity (cell death) = (1- [absorbance of
experimental wells/absorbance of control wells]) × 100%.
LDH release assay. LDH (lactate dehydrogenase) is a stable
cytosolic enzyme that is released upon membrane damage. LDH
activity was measured using a commercial cytotoxicity assay kit
(Roche Diagnostics GmbH, Mannheim, Germany), in which LDH
released in culture supernatants is measured with a coupled enzy-
matic assay, resulting in conversion of a tetrazolium salt into red
formazan product. The bladder cancer cells were treated with var-
ious concentrations of rhsTRAIL for the indicated period of time.
The sample solution (supernatant) was removed and LDH released
from cells was measured in culture medium. The maximal release
was obtained after treating control cells with 1% Triton X-100
(Sigma Chemical Company, St. Louis, MO) for 10 minutes at room
temperature [22]. The necrotic percentage was expressed using the
formula, (sample value/maximal release) × 100%. 
Determination of apoptotic cell death by flow cytometry with
annexin V-FITC staining. Apoptosis was measured using flow
cytometry to quantify the levels of decentable phosphatidylserine
(PS) on the outer membrane of apoptotic cells. Externalized PS on
the outer surface of the cytoplasmic membrane becomes labeled by
fluoresceinlabeled annexin V, which has a high affinity for PS-con-
taining phospholipids bilayers. Bladder cancer cell lines were
seeded in 24-well plates for 24 hours and then exposed to
rhsTRAIL for 20 hours. After a 20 hour incubation TCC cells were
washed twice with PBS and resuspended in 1 ml of binding buffer.
Five hundred microliters of cell suspension was then incubated
with 5 μl of annexin V-FITC and 10 μl of propidium iodide (PI) for
10 min at room temperature in the dark. Annexin V assay was per-
formed using the Apoptotest-FITC Kit (Dako, Glostrup, Den-
mark). The population of annexin V-positive cells was evaluated
by flow cytometry (BD FACScan, Becton Dickinson Immnunocy-
tometry Systems, San Jose, CA, USA) [24].
Determination of apoptotic cell death by fluorescence
microscopy with annexin V-FITC staining. Apoptotic cells were
quantified by fluorescence microscopic method using Apoptotic &
Necrotic & Healthy Cells Quantification Kit from Biotium, Inc.
(Hayward, CA, USA) according to the manufacturer's instruction
[25]. Bladder cells were washed with PBS and detached from cell
culture wells by trypsin. Next, the TCC cells were centrifuged to
discard supernatant, washed with PBS and resuspended in Binding
Buffer (100 μl/sample). To each tube were added: 5 μl of FITC-
Annexin V, 5 μl of ethidium homodimer III and 5 μl of Hoechst
33342 solutions. The samples were incubated at room temperature
for 15 minutes in the dark. After staining the cells were washed
with Binding Buffer and placed on a glass slide and covered with
a glass coverslip. The stained cells were observed under a fluores-
cence inverted microscope IX51 (Olympus, Tokyo, Japan) using
filter set for FITC, TRITC and DAPI. The healthy cells (stained by
Hoechst 33342) emitted blue fluorescence, apoptotic cells (stained
by FITC-Annexin V and Hoechst 33342) emitted green and blue
fluorescence and necrotic cells (stained with ethidium homodimer
III and Hoechst 33342) emitted red and blue fluorescence. Cancer
cells stained with triple colors blue, red and green, were dead cells
progressing from apoptotic cell population. The cells were count-
ed and apoptotic cells were expressed as percentage of total cells.
Expression of TRAIL death receptors. The cell surface expres-
sion of TRAIL death receptors, TRAIL-R1 and TRAIL-R2 on
bladder cancer cells was measured by flow cytometry. The TCC
cells were seeded in 24-well plates for 24 hours. After the time, the
cells were harvested with 0.05% trypsin/ 0.02% EDTA, washed
twice in PBS and incubated for 30 minutes at 4°C with 10 μL of
phycoerythrin-conjugated monoclonal anti-human TRAIL-R1 or
TRAIL-R2 antibody (R&D Systems, Minneapolis, MN, USA).
Cancer cells were then washed and samples were immediately
used for flow cytometric analysis (BD FACScan, Becton Dickin-
son Immnunocytometry Systems, San Jose, CA, USA). The con-
trol consisted of cells in a separate tube treated with PE-labeled
mouse IgG1 or mouse IgG2B (R&D Systems, Minneapolis, MN,
USA) [26].
Statistical analysis. The results are expressed as means ±SD
obtained from three separate experiments. The experimental means
were compared to the means of untreated bladder cancer cells har-
vested parallelly and the data was polled for three replicate exper-
iments performed in quadruplicate (n=12). Statistical significance
was evaluated using the one-way ANOVA followed by the post hoc
test. P-values <0.05 were considered significant.
Results
Cytotoxic effect of TRAIL on bladder cancer cells
The bladder cancer cells were incubated with 50 – 200
ng/ml TRAIL for 20 hours. TRAIL at the concentration
of 50 – 100 ng/ml induced cytotoxic effects on bladder
cancer cells in a dose-dependent manner (Fig. 1). The
SW780 cells were sensitive to TRAIL. In contrast, the
two other bladder cancer cell lines, 647V and T24,
were resistant to TRAIL mediated cell death. The cyto-
toxicity measured by MTT assay after treatment with
TRAIL at the concentration of 100 ng/ml was:
60.15±1.25% in SW780 cells, 16.62±0.61% in 647V
cells and 12.22±0.69% in T24 cells. The ligand con-
centration higher than 100 ng/ml had no significant
influence on its cytotoxicity increase in relation to blad-
der cancer cells which were tested. TRAIL at the con-
centrations of 50 – 200 ng/ml did not induce the lysis
of bladder cancer cells determined in the LDH test.
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Fig. 1. TRAIL-induced cytotoxicity in bladder cancer cells. The
cells incubated for 20 hours with TRAIL at concentrations of 
0 – 200 ng/ml. The percentage of cell death was measured by MTT
cytotoxicity assay. The values represent mean ±SD of three inde-
pendent experiments performed in quadruplicate (n=12). All 
differences are statistically significant in relation to control 
(***p<0.001).
TRAIL-induced apoptosis in bladder cancer cells
TRAIL at the concentration of 50 – 100 ng/ml induced
apoptosis on bladder cancer cells in a dose-dependent
manner. Fig. 2 demonstrates the apoptotic effect of
TRAIL at the concentrations of 50 – 200 ng/ml in can-
cer cells after 20-hour treatment measured by flow
cytometry. The SW780 cells were shown to be sensi-
tive to TRAIL induced apoptosis (59.43±1.11% apop-
totic cells after incubation with 100 ng/ml TRAIL).
The 647V and T24 cells were resistant to TRAIL
mediated apoptosis (16.86±0.82% and 13.01±0.71%
apoptotic cells after incubation with 100 ng/ml TRAIL
respectively). Fig. 3 shows the bladder cancer cells
treated with 100 ng/ml TRAIL for 20 hours observed
under fluorescence microscopy. The apoptotic effect of
TRAIL in bladder cancer cells was similar in both the
flow cytometry and fluorescence microscopy. The
treatment of bladder cancer cells with TRAIL at the
concentration higher than 100 ng/ml had no signifi-
cance on the death cells percentage.
Expression of TRAIL-R1 and TRAIL-R2
on bladder cancer cells
To identify the mechanism of TRAIL-sensitivity and
TRAIL-resistance of bladder cancer cells, the cell sur-
face expression of TRAIL death receptors, TRAIL-R1
and TRAIL-R2 were examined by flow cytometry
(Table 1). The expression of TRAIL-R1 was detected
in less than 5% of each bladder cancer cell line. In con-
trast, TRAIL-R2 is strongly expressed in TRAIL sen-
sitive SW780 cells (45.04±2.11%), whereas TRAIL-
resistant 647V and T24 cells are characterized by low
expression of TRAIL-R2 (2.34±0.86% and 3.93
±1.73% respectively).
Discussion
Soluble or expressed on immune cells (natural killer
(NK) cells, lymphocytes T, monocytes, macrophages,
dendritic cells and neutrophils) molecules of TRAIL
play an important role in antitumor immunity, surveil-
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Fig. 2. TRAIL-induced apoptosis in blad-
der cancer cells. Bladder cancer cell cul-
tures (A) SW780, (B) 647V and (C) T24
after 20-hour treatment with TRAIL at
concentrations of 100 ng/ml. (D) Apoptot-
ic effect of 0 – 200 ng/ml TRAIL in blad-
der cancer cells. The cells incubated for 20
hours with TRAIL at concentrations of 
0 – 200 ng/ml. Detection of apoptotic cell
death by annexin V-FITC staining using
flow cytometry. The values represent mean
±SD of three independent experiments per-
formed in quadruplicate (n=12). All differ-
ences are statistically significant in rela-
tion to control (***p<0.001).
Table 1. The cell surface expression of death receptor TRAIL-R1
and TRAIL-R2 in bladder cancer cells. The values represent mean
±SD of three independent experiments performed in quadruplicate
(n=12).
lance and defense mechanisms against tumor cells [5-
7,14,18,27]. Recombinant human TRAIL used in our
study is a soluble protein based on a naturally occur-
ring ligand. Numerous studies have shown that TRAIL
induces apoptosis in a wide variety of cancer cells and
significantly inhibits growth in xenograft tumor mod-
els [5-9].
TRAIL mediates apoptosis through two death
receptors, TRAIL-R1 and TRAIL-R2, that are
expressed in the cancer cells surface. The interaction
of the ligand and death receptors leads to activation of
the extrinsic apoptosis pathways [1,11]. However,
some tumor cells are resistant to TRAIL-mediated
cytotoxicity. Previous reports suggested that the sensi-
tivity of cancer cells to TRAIL-induced apoptosis can
be correlated to the relative expression of death recep-
tors TRAIL-R1 and TRAIL-R2 or intracellular levels
of antiapoptotic proteins [18-20]. 
The purpose of this study was to investigate the
sensitivity of three human bladder transitional cell
cancer lines to TRAIL-mediated apoptosis. We
demonstrated that the moderately differentiated transi-
tional 647V cells and poorly differentiated transitional
T24 cells are resistant to TRAIL, in contrast to well
differentiated transitional SW780 cells sensitive to
TRAIL-induced cytotoxicity. Our results from detec-
tion of apoptosis by flow cytometry and fluorescence
microscopy with annexin V-FITC and the typical mor-
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Fig. 3. TRAIL-induced apoptosis in bladder
cancer cells. Controls of cells without TRAIL:
(A) SW780, (B) 647V(A) and (C) T24. Apop-
totic effect of 100 ng/ml TRAIL in bladder
cancer cells. Bladder cancer cell cultures (D)
SW780, (E) 647V and (F) T24 after 20-hour
treatment with TRAIL at concentrations of 100
ng/ml. The healthy, viable cells are blue, apop-
totic cells are green. (G) The cells incubated
for 20 hours with TRAIL at concentrations of
0 – 100 ng/ml. Detection of apoptotic cell
death by Hoechst 33342, ethidium homodimer
III and annexin V-FITC staining using fluores-
cence microscopy. The values represent mean
±SD of three independent experiments per-
formed in quadruplicate (n=12). All differ-
ences are statistically significant in relation to
control (***p<0.001).
phological changes determined by Hoechst 33342 con-
firmed that the mechanism of TRAIL mediated cyto-
toxicity on bladder cancer cells is apoptosis. Shimada
et al., Earel et al. and Mizutani et al. confirmed that
some bladder cancer lines, including T24 cells are
resistant to TRAIL-induced apoptosis [26,28,29].
Sensitivity of cancer cells to TRAIL induced apop-
tosis can be modulated at several levels in the apopto-
sis signaling pathways [19]. Numerous mechanisms of
cancer cells escape from apoptosis induction have
been described. The increased expression and muta-
tion of TRAIL death receptors in cancer cells are the
main reason of TRAIL-resistance. The efficacy of cor-
relates with the cell surface expression of TRAIL-R1
and/or TRAIL-R2 in cancer cells has been shown [30].
The upregulation of TRAIL-R1 and/or TRAIL-R2
expression in tumor cells by anticancer agents over-
come the resistance to TRAIL-mediated apoptosis in
cancer cells [18]. We showed that TRAIL-sensitive
SW780 bladder cancer cells expressed high levels of
death receptor TRAIL-R2 on its surface. The TRAIL-
resistant 647V and T24 cells characterized low expres-
sion of TRAIL-R2. 
The cell surface expression of TRAIL-R2 is essen-
tial for TRAIL-induced apoptosis. The TRAIL-R2
gene is located at 8p21-22 and this region is frequent-
ly lost in bladder cancer [31]. The chemotherapeutic
drugs or ionizing radiation induce expression of
TRAIL-R2 in cancer cells surface enhancing the ther-
apeutic potential of TRAIL [17,21,30].
Furthermore, upregulation expression of TRAIL-R2
by doxorubicin, cisplatin and topotecan in renal cancer
cells, doxorubicin and etoposide in leukemia cells and
glioma cells, irinotecan in colon cancer cells enhanced
the responsiveness of these tumor cells to TRAIL-
mediated apoptosis [32-37]. In in vitro study, receptor
TRAIL-R2 contributed to TRAIL-mediated apoptosis
in combination with ionizing radiation [38]. Interferon-
alpha sensitizes human hepatoma cells to TRAIL-
induced apoptosis through DR5 upregulation [39]. His-
tone deacetylase inhibitors modulate the sensitivity of
bladder by increased TRAIL-R2 gene transcription that
correlates with increased TRAIL-R2 surface expres-
sion [29]. These observations, including ours, suggest
that TRAIL-R2 expression might be a reliable indicator
of the cytotoxic effect that could be achieved by recom-
binant soluble TRAIL or agonistic anti-TRAIL-R2 [18].
TRAIL as recombinant soluble TRAIL or agonistic
anti-TRAIL-R1 and anti-TRAIL-R2 antibodies were
introduced in phases I and II of the studies. Although
the clinical trials demonstrate promising results, the
use of TRAIL therapies is only advantageous to patient
with TRAIL-sensitive tumors. This fact showed that
TRAIL as monotherapy will only be effective against
TRAIL-sensitive cancer cells, however most tumors
are resistant to TRAIL induced apoptosis. TRAIL
resistance has been reported in approximately 50% of
tested tumor cell lines thus limiting the use of TRAIL
alone in clinic [14,17,18].
In phase II of the studies the patients with TRAIL-
resistant tumors required the combination of sensitiz-
ing agents (chemotherapy or radiotherapy) and
TRAIL to reverse resistance. Targeted induction of
apoptosis in cancer cells by activation of the death
receptors, particularly TRAIL-R2, should be an ideal
therapeutic strategy to eliminate cancer cells [18,40].
The cytotoxic agents capable of up-regulating the
expression of TRAIL-R2 can sensitize cancer cells to
TRAIL induced apoptosis. Therefore, receptor
TRAIL-R2 is an attractive therapeutic target in cancer
treatment.
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